{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T17:22:05Z","timestamp":1767374525438,"version":"3.37.3"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T00:00:00Z","timestamp":1518652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000864","name":"The Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00702-018-1859-3","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T09:39:47Z","timestamp":1518687587000},"page":"1007-1011","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Who will remain tremor dominant? The possible role of cognitive reserve in the time course of two common Parkinson\u2019s disease motor subtypes"],"prefix":"10.1007","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7237-7008","authenticated-orcid":false,"given":"Talia","family":"Herman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Shema-Shiratzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Arie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Giladi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. M.","family":"Hausdorff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,15]]},"reference":[{"key":"1859_CR1","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/mds.20897","volume":"21","author":"G Alves","year":"2006","unstructured":"Alves G, Larsen JP, Emre M, Wentzel-Larsen T, Aarsland D (2006) Changes in motor subtype and risk for incident dementia in Parkinson\u2019s disease. Mov Disord 21:1123\u20131130","journal-title":"Mov Disord"},{"key":"1859_CR2","doi-asserted-by":"crossref","unstructured":"Arie L, Herman T, Shema-Shiratzky S, Giladi N, Hausdorff JM (2017) Do cognition and other non-motor symptoms decline similarly among patients with Parkinson\u2019s disease motor subtypes? Findings from a 5-year prospective study. J Neurol 264:2149\u20132157","DOI":"10.1007\/s00415-017-8605-x"},{"key":"1859_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1136\/jnnp.2005.081711","volume":"77","author":"DJ Burn","year":"2006","unstructured":"Burn DJ, Rowan EN, Allan LM, Molloy S, O\u2019Brien JT, McKeith IG (2006) Motor subtype and cognitive decline in Parkinson\u2019s disease, Parkinson\u2019s disease with dementia, and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry 77:585\u2013589","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1859_CR4","doi-asserted-by":"crossref","unstructured":"Eisinger RS, Hess CW, Martinez-Ramirez D, Almeida L, Foote KD, Okun MS, Gunduz A (2017) Motor subtype changes in early Parkinson\u2019s disease. Parkinsonism Relat Disord 43:66\u201372","DOI":"10.1016\/j.parkreldis.2017.07.018"},{"key":"1859_CR5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s11910-017-0738-x","volume":"17","author":"SM Fereshtehnejad","year":"2017","unstructured":"Fereshtehnejad SM, Postuma RB (2017) Subtypes of Parkinson\u2019s disease: what do they tell us about disease progression? Curr Neurol Neurosci Rep 17:34","journal-title":"Curr Neurol Neurosci Rep"},{"key":"1859_CR6","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.1600-0404.2010.01344.x","volume":"123","author":"GM Hariz","year":"2011","unstructured":"Hariz GM, Forsgren L (2011) Activities of daily living and quality of life in persons with newly diagnosed Parkinson\u2019s disease according to subtype of disease, and in comparison to healthy controls. Acta Neurol Scand 123:20\u201327","journal-title":"Acta Neurol Scand"},{"key":"1859_CR7","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1001\/archneur.58.10.1611","volume":"58","author":"J Jankovic","year":"2001","unstructured":"Jankovic J, Kapadia AS (2001) Functional decline in Parkinson disease. Arch Neurol 58:1611\u20131615","journal-title":"Arch Neurol"},{"key":"1859_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/acn3.312","volume":"3","author":"V Kotagal","year":"2016","unstructured":"Kotagal V (2016) Is PIGD a legitimate motor subtype in Parkinson disease? Ann Clin Transl Neurol 3:473\u2013477","journal-title":"Ann Clin Transl Neurol"},{"key":"1859_CR9","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1002\/mds.26657","volume":"31","author":"JG Nutt","year":"2016","unstructured":"Nutt JG (2016) Motor subtype in Parkinson\u2019s disease: different disorders or different stages of disease? Mov Disord 31:957\u2013961","journal-title":"Mov Disord"},{"key":"1859_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/mds.25220","volume":"28","author":"M Selikhova","year":"2013","unstructured":"Selikhova M, Kempster PA, Revesz T, Holton JL, Lees AJ (2013) Neuropathological findings in benign tremulous parkinsonism. Mov Disord 28:145\u2013152","journal-title":"Mov Disord"},{"key":"1859_CR11","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1017\/S1355617702813248","volume":"8","author":"Y Stern","year":"2002","unstructured":"Stern Y (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc 8:448\u2013460","journal-title":"J Int Neuropsychol Soc"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00702-018-1859-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-018-1859-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T21:32:53Z","timestamp":1570743173000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00702-018-1859-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,15]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1859"],"URL":"https:\/\/doi.org\/10.1007\/s00702-018-1859-3","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"type":"print","value":"0300-9564"},{"type":"electronic","value":"1435-1463"}],"subject":[],"published":{"date-parts":[[2018,2,15]]},"assertion":[{"value":"2 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"TH, LA, SS declare no financial or other conflicts of interest. Prof. Hausdorff reports Grants from Michael J Fox Foundation, during the conduct of the study. Prof. Giladi serves as a member of the Editorial Board for the Journal of Parkinson\u2019s Disease. He serves as consultant to Teva- NeuroDerm, Biogen, Pharma2B, Denali, Abbvie, AccelMed, Monfort and UCB. He receives royalties from LTI and payment for lectures at Teva, UCB, Abviee, Bial and Movement Disorder Society. He received research support from the Michael J Fox Foundation, the National Parkinson Foundation, the European Union 7th Framework Program and the Israel Science Foundation as well as from Teva NNE program, Biogen, LTI, and Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}